https://scholars.lib.ntu.edu.tw/handle/123456789/577137
標題: | DEVELOPMENT of ENGINEERED CARTILAGE PRODUCT from BONE MARROW MESENCHYMAL STEM CELLS: AN EXAMPLE in TAIWAN | 作者: | Chen Y.-C Liu H.-C Lin F.-H Chang C.-H. Lin, Feng-Huei |
關鍵字: | Bone marrow mesenchymal stem cell; Cartilage defect; Cartilage regeneration; Collagen | 公開日期: | 2021 | 卷: | 24 | 期: | 1 | 來源出版物: | Journal of Musculoskeletal Research | 摘要: | Cartilage can redistribute human body's daily loads and decrease the friction force in the diarthrodial joints. However, it may be injured due to trauma, sports injury, biomechanical imbalance, and genetic disease. Microfracture (MF), osteochondral autograft transplantation (OAT), and autologous chondrocyte implantation (ACI) are the most common treatment procedures in the hospital. Recently, the concept of tissue engineering involving the combination of cells, scaffolds, and bioactive signals has inspired researchers. Our team of researchers synthesized a tri-copolymer from biological polymer by using gelatin, chondroitin-6-sulfate, and hyaluronic acid through cross-linking reaction. Lacuna formation could be seen in the tri-copolymer surrounding the chondrocytes, and some newly formed glycosaminoglycan was found in the engineered cartilage. Considering the dedifferentiation possibility of chondrocyte, bone marrow mesenchymal stem cells (BMSCs) become an ideal cell source for cartilage tissue regeneration, since they can be easily harvested from adult tissue, and be expanded in vitro. In an in-vivo porcine pilot study, the results showed that the defect site could be regenerated by BMSCs/collagen gel, and is formed with fibro/hyaline mixed cartilage tissue after implantation for six months. Several clinical studies using BMSCs for cartilage defect treatment were also conducted recently; clinical outcomes such as IKDC, Lysholm, and Tegner scores improved when the cartilage defects were repaired by several millions of mesenchymal stem cells, and there is no tumor formation after being treated with BMSCs during the 10-year follow-up. Moreover, recently a commercial BMSCs/collagen gel composite for cartilage repair was developed in Taiwan and clinical trial was conducted in 2008; the results showed that there is an improvement in IKDC and MRI scores during the nine-year follow-up. It seems that using an engineered cartilage made from BMSCs/collagen gel for cartilage defect treatment is a promising method. ? 2021 World Scientific Publishing Company. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103554237&doi=10.1142%2fS0218957721300015&partnerID=40&md5=81a1263d3ed1dcdac75af3241bbd9ae8 https://scholars.lib.ntu.edu.tw/handle/123456789/577137 |
ISSN: | 2189577 | DOI: | 10.1142/S0218957721300015 | SDG/關鍵字: | chondroitin 6 sulfate; collagen gel; gelatin; glycosaminoglycan; hyaluronic acid; Article; bone marrow mesenchymal stem cell; carcinogenesis; cartilage; cell dedifferentiation; chondrocyte; cross linking; human; Lysholm score; mesenchymal stem cell; nonhu |
顯示於: | 醫學工程學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。